Company intelligence / Profile preview

AbFero Pharmaceuticals

Lexington, Massachusetts, United Statesabferopharmaceuticals.com ↗

Ownership: Private
Employees: ~2
Development stage: Phase 1

Overview

AbFero completed three clinical trials with its lead iron chelator SP-420, including a Phase 1a in healthy volunteers, Phase 1b in patients with transfusion-dependent β-thalassemia, and Phase 1c in healthy volunteers to support TIW dosing in TIO.

Therapeutic areas: OphthalmologyHematologyCardiovascularNeurology
Modalities: Small molecules (iron chelators)
Industry: Biotech

Drug pipeline

1 asset

SP-420

Phase 1

Indications: Transfusional iron overload, Age-related macular degeneration, Parkinson's disease

Partnerships

University of Pennsylvania (discussions for testing SP-420 as AMD treatment)

Beyond the preview

Go deeper on AbFero Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AbFero Pharmaceuticals.

Explore the full profile